RSNA: BMI Linked to Detection of Larger Breast Tumors
TUESDAY, Nov. 21, 2017 -- Body mass index (BMI) is associated with detection of large breast tumors (>2 cm) among screen-detected and interval cancers, according to a study scheduled to be presented at the annual meeting of the Radiological Society of North America, held from Nov. 26 to Dec. 1 in Chicago.
Fredrik Strand, M.D., from the Karolinska University Hospital in Stockholm, and colleagues examined a population-based screening cohort of 2,358 cases of invasive breast cancer incident between 2001 and 2008. The authors estimated multiple adjusted odds ratios (ORs) for the correlation between percent density (PD), BMI, and other patient characteristics with tumor size larger than 2 cm.
The researchers found that both BMI and PD correlated with having a large tumor at diagnosis (ORs, 1.33 per 5 kg/m² and 1.26 per 10 percent PD, respectively) for screen-detected cancers. Only BMI was associated with having a large tumor for interval cancers (OR, 1.56), while PD correlated with having a small tumor (OR, 0.81). Among screen-detected cases only, nulliparity was significant (OR, 1.45). Compared with small tumors, large tumors correlated with worse prognosis (hazard ratio, 2.66). For interval cancers only, women with higher BMI had a worse prognosis than women with lower BMI (hazard ratio, 2.01).
"Our study suggests that when a clinician presents the pros and cons of breast cancer screening to the patient, having high BMI should be an important 'pro' argument," Strand said in a statement. "In addition, our findings suggest that women with high BMI should consider shorter time intervals between screenings."
© 2020 HealthDay. All rights reserved.
Posted: November 2017
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.